# Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent

Source: https://onco.cc/trials/nct07005583/  
OnCo record `nct07005583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab and olaparib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07005583 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 46 participants, started 2025-06-30 and due to reach its primary completion in 2027-05-30. Interventions recorded: QL1706 Plus Olaparib. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "Female breast cancer patients aged ≥18 and ≤75 years, with histologically or cytologically confirmed recurrent or metastatic triple-negative breast cancer (TNBC) as defined by the latest ASCO/CAP guidelines (based on the most recent biopsy or other pathological specimens)". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07005583
- Phase: 2
- Setting: Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07005583: https://clinicaltrials.gov/study/NCT07005583

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/), [Olaparib](https://onco.cc/drugs/olaparib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07005583.json